Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against ZIOPHARM Oncology, Inc. And Advises Investors With Losses To Contact The Firm

TCRT

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against ZIOPHARM Oncology, Inc. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims against ZIOPHARM Oncology, Inc. (“ZIOPHARM” or the “Company”) (Nasdaq: ZIOP) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired ZIOPHARM shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the Company’s July 14, 2016 announcement that a brain cancer patient in a clinical trial for its experimental gene therapy, Ad-RTS-hIL-12, died and that there was a second patient death in a gene therapy study unrelated to the Ad-RTS-hIL-12 one. The spokesperson stated that the Company did not yet inform the U.S. Food & Drug Administration about the death. Upon release of this news, stock prices of ZIOPHARM declined. The Company was trying to raise $50 million in a stock offering this week but the deal was abandoned on the night of July 14, 2016 according to an email sent by Jefferies & Co. bankers.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Goldberg Law PC, Los Angeles
Michael Goldberg, Esq., 800-977-7401
Brian Schall, Esq., 800-977-7401
info@goldberglawpc.com
http://www.Goldberglawpc.com
https://twitter.com/search?q=goldberglawpc&src=typd
https://www.facebook.com/pages/Goldberg-Law-PC/850505465033804?fref=ts



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today